Smirnov, Denis S.
Ashton, Nicholas J.
Blennow, Kaj
Zetterberg, Henrik
Simrén, Joel
Lantero-Rodriguez, Juan
Karikari, Thomas K.
Hiniker, Annie
Rissman, Robert A.
Salmon, David P.
Galasko, Douglas http://orcid.org/0000-0001-6195-3241
Funding for this research was provided by:
National Institute on Aging (P30-AG062429)
Forskningsrådet för Arbetsliv och Socialvetenskap (2018-02531)
H2020 European Research Council (681712)
Alzheimer's Drug Discovery Foundation (201809-2016862, RDAPB-201809-2016615)
Alzheimer's Association ((#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C)
Medicinska Forskningsrådet (2017-00915)
Article History
Received: 5 October 2021
Revised: 8 February 2022
Accepted: 9 February 2022
First Online: 23 February 2022
Declarations
:
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx, and Red Abbey Labs, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). DPS has served as a consultant for Biogen and Aptinyx. DG has served as a consultant for Biogen, Roche, General Electric Healthcare, Fujirebio, Amprion, Generian and Cognition Therapeutics.